Evotec To Attend Upcoming Investor ConferencesHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)Evotec To Attend Upcoming Investor ConferencesACCESSWIREJanuary 2, 2020ReblogShareTweetShareHAMBURG, GERMANY / ACCESSWIRE / January 2, 2020 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that its management will be presenting at and attending the following upcoming conferences in January and February 2020:ODDO BHF Forum 2020, Lyon, France- Date: Thursday, 09 January 2020 to Friday, 10 January 2020- Venue: Lyon, France- Attendee: Enno Spillner, Chief Financial Officer38th J.P. Morgan Healthcare Conference, San Francisco, USA- Date: Monday, 13 January 2020 to Thursday, 16 January 2020, Presentation: 16 January 2020, 11.00 am PT(2.00 pm EST, 7.00 pm GMT, 8.00 pm CET)- Webcast:
Click here for the webcast- Venue: San Francisco, USA- Attendee: Dr Werner Lanthaler, Chief Executive Officer19th German Corporate Conference 2020, jointly hosted by UniCredit and Kepler Cheuvreux, Frankfurt am Main, Germany- Date: Tuesday, 21 January 2020, Presentation: 21 January 2020, 4.00 pm CET- Venue: Frankfurt am Main, Germany- Attendee: Dr Werner Lanthaler, Chief Executive OfficerBankhaus Lampe German Equity Forum, London, UK- Date: Thursday, 30 January 2020- Venue: London, UK- Attendee: Dr Werner Lanthaler, Chief Executive Officer8th Business Forum of LBBW (8. Unternehmensforum der LBBW)- Date: Thursday, 13 February 2020- Venue: Stuttgart, Germany- Attendee: Enno Spillner, Chief Financial OfficerABOUT EVOTEC SEEvotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 2,900 employees provide the highest quality stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare diseases and women's health. On this basis, Evotec has built a broad and deep pipeline of approx. 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to www.evotec.com and follow us on Twitter @Evotec.FORWARD LOOKING STATEMENTS Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.Contact Evotec SE:Gabriele HansenSVP Corporate CommunicationsMarketing & Investor RelationsPhone: +49.(0)40.56081-255gabriele.hansen@evotec.comSOURCE: Evotec AGView source version on accesswire.com: https://www.accesswire.com/571809/Evotec-To-Attend-Upcoming-Investor-ConferencesReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextFormer Liverpool chief exec Ian Ayre says club restored to the top by owners’ plan of ‘evolution not revolution’The IndependentHusky CEO slams Ottawa for derailing projects with politicsYahoo Finance CanadaRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoMost face masks won’t protect you from the coronavirusYahoo FinanceStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceStock market live updates: Stock futures climb after historic rout; coronavirus fears persistYahoo FinanceCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceBankrupt Boy Scouts may need to sell Norman Rockwell art to pay sexual abuse victimsUSA TODAYSomething 'dangerous' is happening beneath the surface of the market selloffYahoo FinanceBeyond Meat beats on Q4 earnings, founder says 'we would be crazy not to invest in growth right now'Yahoo Finance